Callan Family Office LLC purchased a new position in shares of Ventas, Inc. (NYSE:VTR - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 25,940 shares of the real estate investment trust's stock, valued at approximately $2,303,000.
A number of other hedge funds and other institutional investors have also modified their holdings of VTR. Dynamic Wealth Strategies LLC acquired a new stake in Ventas during the first quarter worth approximately $25,000. Wiser Advisor Group LLC acquired a new position in Ventas in the 3rd quarter valued at $27,000. Silvant Capital Management LLC acquired a new position in Ventas in the 2nd quarter valued at $28,000. Meeder Asset Management Inc. acquired a new position in Ventas in the 2nd quarter valued at $30,000. Finally, IFC & Insurance Marketing Inc. purchased a new position in shares of Ventas during the 4th quarter worth $30,000. 94.18% of the stock is currently owned by hedge funds and other institutional investors.
Ventas Stock Up 0.7%
Shares of NYSE VTR opened at $93.32 on Friday. Ventas, Inc. has a 52-week low of $66.38 and a 52-week high of $101.60. The firm has a fifty day moving average of $91.36 and a 200-day moving average of $87.08. The stock has a market capitalization of $47.87 billion, a PE ratio of 172.81, a P/E/G ratio of 2.15 and a beta of 0.69. The company has a quick ratio of 0.44, a current ratio of 0.44 and a debt-to-equity ratio of 0.86.
Ventas (NYSE:VTR - Get Free Report) last issued its earnings results on Wednesday, July 29th. The real estate investment trust reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.01. The business had revenue of $1.73 billion for the quarter, compared to analyst estimates of $1.68 billion. Ventas had a return on equity of 1.99% and a net margin of 4.08%.The business's quarterly revenue was up 21.7% on a year-over-year basis. During the same period last year, the company posted $0.87 EPS. On average, analysts anticipate that Ventas, Inc. will post 3.89 EPS for the current year.
Insider Transactions at Ventas
In other news, Director Michael J. Embler purchased 2,500 shares of the company's stock in a transaction on Wednesday, June 3rd. The stock was bought at an average cost of $78.81 per share, for a total transaction of $197,025.00. Following the completion of the purchase, the director directly owned 19,202 shares of the company's stock, valued at $1,513,309.62. The trade was a 14.97% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.53% of the company's stock.
Wall Street Analyst Weigh In
VTR has been the topic of several analyst reports. Raymond James Financial initiated coverage on Ventas in a report on Tuesday, June 16th. They set an "outperform" rating and a $94.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on Ventas from $93.00 to $94.00 and gave the company an "overweight" rating in a research note on Monday, May 11th. Scotiabank reduced their target price on Ventas from $95.00 to $88.00 and set a "sector perform" rating on the stock in a research report on Thursday, June 18th. Weiss Ratings raised Ventas from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, July 21st. Finally, Royal Bank Of Canada lifted their price target on Ventas from $98.00 to $99.00 and gave the company an "outperform" rating in a report on Friday, August 14th. Fifteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $98.00.
Read Our Latest Stock Report on VTR
Ventas Company Profile
(
Free Report)
Ventas, Inc NYSE: VTR is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.
Ventas' business model combines property ownership with active asset management and capital markets activity.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Ventas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventas wasn't on the list.
While Ventas currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
